Worldwide Clinical Trials (Worldwide) last week announced it has acquired Continuum Clinical’s Late Stage research practice.
According to a press release, the acquisition will bolster Worldwide’s capacity to “help life sciences industry sponsors establish evidence of value at every stage of the product life cycle.”
Worldwide, a full-service contract research organization, specializes in central nervous system, cardiovascular, metabolic, immune-mediated inflammatory disorders, oncology and rare disease research.
“Sponsors, healthcare providers and regulators are seeking better data and evidence to design, deliver and manage healthcare,” Worldwide President and Chief Operating Officer Peter Benton said in a statement. “CROs can be their greatest ally – by helping to accelerate generation of evidence and real-world outcomes data on the clinical, economic and humanistic impact of new drug and device solutions.”
Continuum Clinical Late Stage President Jeff Trotter will join Worldwide to head the Worldwide Evidence business unit.
“Worldwide Clinical Trials is the perfect match for our Late Stage practice,” Trotter said in a statement. “As the leading midsized CRO, Worldwide’s bespoke, hands-on approach mirrors our client-service philosophy and will enable us to serve clients with substantially expanded resources to support sponsors’ medical affairs, health economics, and evolving real-world evidence departments.”